BAM
LYRA

Belpointe Asset Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Belpointe Asset Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74
Closed -$11.6K – 3801
2022
Q4 		$11.6K Buy
+74
New +$14.6K ﹤0.01% 2540

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's LYRA Position: Q1 2023 in Review

Belpointe Asset Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2023, closing a stake of 74 shares — an estimated $11.6K sold.

Belpointe Asset Management first reported a position in LYRA in Q4 2022 and held it in 1 quarter. The position peaked at $11.6K in Q4 2022. 31 funds tracked by Wall St. Rank hold LYRA as of Q1 2023.

  • Belpointe Asset Management reported no remaining LYRA THERAPEUTICS INC position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 74 LYRA THERAPEUTICS INC shares in Q1 2023, an estimated $11.6K.
  • Belpointe Asset Management first reported a position in LYRA THERAPEUTICS INC in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's LYRA THERAPEUTICS INC position peaked at $11.6K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.